Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

r at 5:45 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

The following posters will be presented by the investigators from The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital:

Activities Of Commonly Used Tyrosine Kinase Inhibitors Against Wild Type c-KIT And Potential Impact On Normal Hematopoiesis.  Session Name: Molecular Pharmacology, Drug Resistance: Poster III.  Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.

The Combination Of FLT3 Inhibition And Hypomethylation Confers Synergistic Antileukemic Effects On FLT3-ITD Positive AML Cell Lines And Primary Cells: Session Name: Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster III.  Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.

The abstracts and posters can be accessed on the ASH website at http://hematology.org.

Third Quarter Results
Revenues were $7.7 million and $4.3 million for the quarters ended September 30, 2013 and 2012, respectively.  The increase of $3.4 million was primarily due to acceleration in the recognition of license fee revenue related to the Company's collaboration with Astellas Pharma.  In March 2013, the Company received a notice of termination of the agreement from Astellas, which termination was effective September 2013. 

Research and development expenses were $4.5 million and $8.2 million for the quarters ended September 30, 2013 and 2012, respectively.  The decrease of $3.7 million was primarily due to lower quizartinib research and development expenses.  This resulted from a reduction in the number of patients being treated and followed in our Phase 2 clinical trial, in which enrollment was completed in late 2011. 

General and administrative expenses were
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... UK (PRWEB) October 30, 2014 Caustic soda ... epoxy resins and polycarbonates. At present, China takes lead in ... , Dow, which possesses a number of facilities in the ... in the world caustic soda market in terms of output ... forecast to grow on average by 3% per year in ...
(Date:10/31/2014)... 31, 2014 Jeffrey T. Manuel, assistant ... Studies within the College of Arts and Sciences, is ... the history of alcohol-based fuels in Illinois. , ... have been working to build Illinois’ biofuels industry for ... aspect of the state's agricultural and business history. ...
(Date:10/31/2014)... October 31, 2014 The report ... Rice), Formulation (Plain, Flavored, Sweetened, Unsweetened), Channel (Supermarket, ... Global Trends & Forecast to 2018," defines and ... analysis and forecast of revenue and volume for ... is projected to reach $14 Billion by 2018 ...
(Date:10/31/2014)... 31, 2014 Stronger investment from ... finance and consumer electronics will help fuel new ... research firm IBISWorld has added a report on ... industry report collection. , The Biometrics Scan Software ... technologies such as fingerprint, iris, retina and face ...
Breaking Biology Technology:China to Dominate Caustic Soda Market Through 2018, Says Merchant Research & Consulting in Its New Study 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 3
... measures urinary 11dhTxB2 to assess aspirin effectDENVER, March ... CONX), a worldwide developer and marketer of diagnostic ... its AspirinWorks(R) Test March 29 - 31 at ... Scientific Session. The annual meeting will take place ...
... regulatory hiccups, the number of biosimilars in the ... patent expiry of key biopharmaceuticals has opened up ... of biosimilars. In addition, payers, perception of biosimilars, ... their safety, efficacy and affordability, will further bolster ...
... 18 , - ... and Compliance Challenges of Radiologic Technologists, Managers , ... Mosby,s Imaging Suite,( http://www.mosbysimagingsuite.com ), the first fully ... education, communication and,compliance challenges of radiologic technologists and ...
Cached Biology Technology:Corgenix to Exhibit AspirinWorks(R) Test at ACC.09 2Corgenix to Exhibit AspirinWorks(R) Test at ACC.09 3The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan 2The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan 3The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan 4New Online Imaging Suite Boosts Healthcare Imaging Efficiency, Productivity, and Revenues 2New Online Imaging Suite Boosts Healthcare Imaging Efficiency, Productivity, and Revenues 3New Online Imaging Suite Boosts Healthcare Imaging Efficiency, Productivity, and Revenues 4
(Date:10/30/2014)... Carolina State University researchers have developed a suite of ... dogs and humans, which has applications in everything from ... pets. , "We,ve developed a platform for computer-mediated communication ... new avenues for interpreting dogs, behavioral signals and sending ... David Roberts, an assistant professor of computer science at ...
(Date:10/30/2014)...  Securus Technologies, a leading provider of ... public safety, investigation, corrections and monitoring, announced ... to its THREADS™ product, which utilizes sophisticated ... and focused leads for investigators. ... through identifying and delivering solutions serving the ...
(Date:10/29/2014)... their hair as a consequence of chemotherapy will benefit ... scalp cooling technology that prevents hair loss. , The ... by global scalp cooling manufacturing company, Paxman Coolers, of ... of the University of Huddersfield. , The research will ... a background in the pharmacology of cancer treatment, which ...
Breaking Biology News(10 mins):New tech aims to improve communication between dogs and humans 2Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2
... school early with dreams of being a rock star ... microbiology and his studies into the social lifestyle of ... leading cause of death in Cystic Fibrosis patients and ... Steve Diggle, Royal Society University Research Fellow (and part-time ...
... team of scientists in the United Kingdom and ... microbes have become progressively more resistant to antibiotics ... continues despite apparent more stringent rules on use ... sewage treatment technology that broadly improves water quality ...
... The Johns Hopkins University School of Medicine reveal new details ... in the March issue of The Journal of General ... ion channels spontaneously close by inactivation, a process distinct from ... important for a variety of biological processes, including the timing ...
Cached Biology News:A rocking good lecture 2
Sirtuin 7 (SIRT7) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: Other Recommended Storage: Long term: -20C; Short term: +4C...
... designed for your specific applications and built ... synthesis platform. Thousands of customer specified sequences ... can provide assistance with custom sequence design. ... our comprehensive Custom DNA Microarray Service. ...
... The RSH-4000 is the only microplate sealer ... offers long walkaway times with a variety ... , Fully automated with integrated stacker and ... PlateCrane EX for use in small workcells ...
... Microarrays designed for RNA aptamer screening ... flexible and powerful Paraflo microfluidic on-chip synthesis ... of our comprehensive DNA/RNA Aptamer Microarray Service. ... 2-F RNA Aptamer Microarray contains greater than ...
Biology Products: